Multihance at 3 Tesla (3T) in Brain Tumors

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Compare the efficacy of MultiHance and Magnevist

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bracco Diagnostics, Inc

Criteria

Inclusion Criteria:

• Was 18 years or older

• Provided written informed consent

• Scheduled for MRI

• Confirmed or highly suspected to have brain tumor(s) and willing to undergo two MRI exams within 14 days

Exclusion Criteria:

• Pregnant or lactating females

• Allergy to one or more of the ingredients in the products or hypersensitivity to any metals

• Congestive heart failure, class IV

• Previous stroke in the past year

• Received another contrast agent within 24 hours pre and post each exam

• Investigational product

• Contraindications to MRI

• Severe claustrophobia

• Surgery with 3 weeks prior

• Steroid therapy or radiosurgery between two exams